Kuo Peiwen, Le Quynh-Thu
Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA.
Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA
Glycobiology. 2014 Oct;24(10):921-5. doi: 10.1093/glycob/cwu062. Epub 2014 Jun 27.
Radiation therapy is a main stay in treating solid tumors and plays a significant role in definitive and adjuvant therapy. Unfortunately, local control remains a challenge, in which the success of radiotherapy is largely dictated by tumor hypoxia, DNA damage repair and the antitumor immune response. Extensive efforts have therefore been devoted to targeting the factors that attenuate tumor radiosensitivity, although with limited success. Mounting evidence suggests that tumor and endothelial cells may utilize galectin-1 (Gal-1) for protection against radiation through several mechanisms. Targeting Gal-1 in combination with radiotherapy provides an exciting approach to address several radiation-prohibitive mechanisms.
放射治疗是实体瘤治疗的主要手段，在根治性和辅助性治疗中发挥着重要作用。不幸的是，局部控制仍然是一个挑战，其中放射治疗的成功很大程度上取决于肿瘤缺氧、DNA损伤修复和抗肿瘤免疫反应。因此，人们已经付出了大量努力来靶向那些减弱肿瘤放射敏感性的因素，尽管成效有限。越来越多的证据表明，肿瘤细胞和内皮细胞可能通过多种机制利用半乳糖凝集素-1（Gal-1）来抵抗辐射。将Gal-1作为靶点与放射治疗相结合，为解决多种阻碍放疗的机制提供了一种令人兴奋的方法。
